Executive Health Programs: Why Inflammaging Is the Missing Biomarker in Corporate Wellness

Chronic, low-grade inflammation, sometimes called inflammaging, is the biological driver behind rising healthcare costs, lost productivity, and burnout in high-value employee populations, yet almost no corporate wellness programme measures it directly. Executive health programmes track cholesterol, blood pressure, and self-reported stress, but these markers miss the immune-aging signal that actually predicts future illness. Closing that gap requires a different kind of measurement: an at-home biological age test that tracks chronic inflammation through IgG glycosylation, the sugar structures coating antibodies in the immune system, giving benefits leaders a single trackable number tied to programme effectiveness rather than participation.

See how this applies across clinical and corporate settings in our guide, GlycanAge for Healthcare Providers, Functional Medicine Clinics & Corporate Wellness Programs.

What is inflammaging, and why is it a blind spot in most executive health programmes?

Inflammaging is the chronic, low-grade systemic inflammation that builds gradually with age and accelerates biological aging. Elevated inflammatory markers predict higher mortality risk, and three out of every five deaths are tied to chronic inflammatory disease. Most existing biomarkers, including the panels used in standard executive health screenings, capture acute inflammation, the short-term spike from an injury or infection, not the chronic, low-grade kind that quietly drives cardiovascular disease and neurodegenerative disorders over years. This is why a workforce can pass every annual health screening and still be accumulating biological age faster than its birth certificate suggests: the tools in most corporate health programmes were never built to see it. 

How is biological age different from chronological age, and why does that distinction matter for benefits planning?

Biological age measures how fast a person's body is functionally aging, distinct from chronological age, which is simply the years elapsed since birth. Chronological age is non-modifiable, everyone accumulates it at the same rate, while biological age reflects physiological health and functional capacity and varies significantly between people of the same chronological age, driven by lifestyle, stress, and other modifiable factors. For employers, this distinction matters because aging is the single biggest risk factor for chronic disease, and a workforce's biological age, not its birthdate, is what predicts future healthcare utilization and productivity loss. A benefits team that tracks biological age can show, in concrete terms, whether stress management, movement, or sleep initiatives are changing the biology tied to future illness, rather than relying on attendance figures alone.

How does GlycanAge actually measure whether a wellness intervention is working?

GlycanAge measures active, current chronic inflammation through IgG glycosylation, the sugar structures attached to immune antibodies that shift measurably in response to lifestyle change. Because glycans sit at the interface of genetics and environment, they respond to real interventions: diet, exercise, stress reduction, sleep, and medical treatment all move the result. Published research spanning more than a decade identifies the glycan clock as one of the first aging biomarkers shown to reverse with simple lifestyle interventions, and it is positioned as the aging biomarker most responsive to lifestyle and medical change. 

"GlycanAge is responding to interventions. It can tell me whether something I'm doing is good or not. I can see the integration of my stress, diet, and exercise into a single number — and one of these glycans is the best predictor of cardiovascular events, heart attack and stroke. When that number goes up, it's better to change something now."

— Prof. Gordan Lauc, Professor of Biochemistry and Molecular Biology, University of Zagreb, and Co-Founder & Chief Scientific Officer, GlycanAge

For a corporate programme, this means a pre- and post-intervention GlycanAge test can show, in a single number, whether a stress reduction programme or fitness benefit changed employee biology, not just self-reported wellbeing. 

Why not just use hs-CRP or an epigenetic clock instead?

Chronic inflammation drives biological aging, but the biomarkers used to measure it are not interchangeable. IgG glycans offer a measure of active chronic inflammation that changes fast enough to track interventions yet stays stable enough to filter noise, unlike high-sensitivity CRP, a blood marker of acute inflammation, or epigenetic clocks, which estimate age from DNA methylation patterns. GlycanAge is built on this biomarker, using three primary indexes, Glycan Shield, Glycan Youth, and Glycan Mature, alongside two supportive indexes, Glycan Median and Glycan Bisection, to give a fuller picture of where inflammation is concentrated in the immune system. For an executive health programme already running standard blood panels, this is the additional layer that shows whether screening results are translating into slower biological aging over time, rather than a duplicate of what a CFO's annual physical already covers. 

Is inflammaging testing only relevant for executive or high-stress employee populations?

Biological age testing is most immediately useful for populations under sustained occupational stress, because chronic workplace stress is one of the clearest modifiable drivers of accelerated immune aging. Executives and high-performers managing constant workload pressure are a natural starting cohort for any employer piloting biological age testing, since this group typically has the budget allocation and the clearest before-and-after story to tell finance stakeholders. That said, the underlying biology applies to any employee population: sedentary habits, poor sleep, and chronic stress accelerate biological aging regardless of job title, while quality sleep, exercise, and relaxation practices decelerate it. A phased rollout, starting with an executive or high-stress cohort before expanding company-wide, gives HR teams a manageable pilot with a clear cost-benefit case before broader investment.

What would a corporate rollout of biological age testing actually look like in practice?

A corporate rollout starts with a baseline test across the population being tracked, followed by a retest matched to the intervention being evaluated — typically 6 to 12 months out for lifestyle-based programmes such as stress management, sleep, or fitness initiatives, or 3 to 4 months for pharmaceutical or hormonal interventions — to see whether the programme moved the number. Measuring and assessing biological age accurately and regularly enables personalized recommendations by doing three things: establishing a baseline for each participant's current health, revealing where individualized intervention is needed rather than applying a one-size-fits-all wellness plan, and tracking progress in a way that motivates continued participation. For a workforce, this typically means offering the test as part of an executive health benefit or a targeted pilot with a high-value population, pairing each result with expert interpretation so employees understand what their number means and what to do next. Every GlycanAge test gives participants access to a self-booked 1:1 Result Interpretation Call, which is where that expert layer gets delivered rather than left to a raw report. 

How often should employees be retested to show programme impact within a budget cycle?

Retesting cadence should match the intervention timeline being evaluated: roughly 6 to 12 months for lifestyle-based programmes, giving biology enough time to shift, or 3 to 4 months where a pharmaceutical or hormonal intervention is involved, while keeping the feedback loop tight enough to inform programme decisions within a single budget cycle. Corporate programmes can build this into an annual or bi-annual testing cadence within benefits planning without waiting years for a signal. This is also where reviewing individual results adds diagnostic-free value for programme design: comparing the actions each participant took between tests against the resulting change in biological age lets a wellness provider start distinguishing which interventions actually moved the needle for that population. 

Can a single biomarker really justify a wellness spend to a CFO?

A biomarker justifies programme spend when it predicts future health outcomes better than chronological age and changes measurably in response to the interventions being funded. Among the criteria the American Federation for Aging Research outlines for an ideal aging biomarker is predictive power: the ability to forecast future health and longevity better than chronological age alone. 

"It definitely cheered me up — I came out about sixteen years younger than my real age. I've been tracking it for nearly ten years now, and for long-term tracking of health, it's really great."

— Prof. Tim Spector, Department of Twin Research and Genetic Epidemiology, King's College London 

For finance stakeholders comparing programme spend to outcomes, a biological age figure gives immediate, intuitive context that a red-amber-green cholesterol ratio cannot: whether an employee's biology looks years older or younger than their birth certificate says. 

Executive health programmes that want to prove their wellness spend is changing biology, not just attendance, can start with a pilot cohort and a baseline GlycanAge test. Visit the Healthcare Providers page to build a corporate testing pathway, or explore partnering with GlycanAge to bring biological age testing into an existing executive health or corporate wellness offering.

Give your executive health programme a biomarker that proves it works. Baseline your highest-value population, track the change, and show finance the number that matters. 

Explore Healthcare Provider Partnerships →

External sources

• https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.982609/full — Mijakovac A, Frkatović A, Hanić M, Ivok J, Martinić Kavur M, Pučić-Baković M, Spector T, Zoldoš V, Mangino M, Lauc G. Heritability of the glycan clock of biological age. Front Cell Dev Biol. 2022;10:982609. 

• https://pubmed.ncbi.nlm.nih.gov/15215265/ — Butler RN, Sprott R, Warner H, Bland J, Feuers R, Forster M, Fillit H, Harman SM, Hewitt M, Hyman M, Johnson K, Kligman E, McClearn G, Nelson J, Richardson A, Sonntag W, Weindruch R, Wolf N. Biomarkers of aging: from primitive organisms to humans. J Gerontol A Biol Sci Med Sci. 2004;59(6):B560-B567.